Charlotte-based CBD company cbdMD YCBD reported its second-quarter fiscal 2023 results late Monday, revealing an improved net loss and significant reductions in selling, general and administrative (SG&A) costs.
"This is one of the best operating results we have had since the company acquired the cbdMD brand…We reduced SG&A expenses by an annualized $24 million year over year," said Ronan Kennedy, cbdMD's Interim CEO and CFO in a press release.
The decrease in SG&A costs represents an annualized spending reduction of $24 million yearly. In addition, the company reported a net loss of $1.4 million on sales of $6.2 million for the quarter, compared to a net loss of $5.0 million on sales of $9.6 million in the same period last year.
Financial Highlights from Q2 Fiscal 2023:
- Net sales for Q2 2023 were $6.2 million, a 2.5% increase from the previous quarter.
- However, net sales for Q2 2023 were down 35% compared to Q2 2022.
- Net sales for the first six months of 2023 were $12.3 million, a significant decrease from $18.9 million in the same period last year.
- Direct-to-consumer (DTC) net sales for Q2 2023 were $4.9 million, a 26% decline from Q2 2022.
- E-commerce net sales remained flat sequentially.
- Wholesale sales for Q2 2023 were $1.35 million, a 15% increase from the previous quarter.
- However, wholesale net sales were down 56% compared to Q2 2022.
- The company reduced SG&A costs by $6.0 million compared to Q2 2022, representing $24 million in annualized spending reductions.
- Loss from operations for Q2 2023 improved by approximately $3.6 million or 72% compared to Q2 2022.
- Non-GAAP adjusted operating loss for Q2 2023 was approximately $0.8 million, showing an improvement of $1.8 million sequentially.
- Loss from operations for the first six months of 2023 was approximately $5.4 million, a decrease from $30.2 million in the same period last year.
- Non-GAAP adjusted operating loss for the first six months of 2023 was $3.5 million, down from $8.8 million in the prior year's comparative period.
Price Target
cbdMD stocks were trading 6.65% lower on Monday, after market close, at $2.03 per share.
See Also:
cbdMD Secures $2.8M Via Underwritten Public Offering Of Common Stock
cbdMD Expands Its Reach To The United Kingdom With Launch On Amazon UK
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.